Finance Watch: Funding Alternatives Become The Norm In Tough Public Markets

Vivo’s Public Fund Has $740m For Small To Mid-Caps

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.